The evaluated tumor markers (CEA and CA19-9) were significantly lower at the time of initiation of chemotherapy (CEA, P = 0.004; CA19-9, P < 0.001) in patients with single-organ pulmonary metastases than tumor markers in those with other forms of mCRC. The gene discussed is CEACAM5; the disease is neoplasm.